CA-ANDERSEN-GLOBAL
Efter den hurtige udvidelse i Afrika forener Andersen Global nu sine afrikanske medlemsfirmaer under brandet ”Andersen”. Som en del af denne overgang vil fem tidligere samarbejdspartnere blive medlemsfirmaer af Andersen Global, hvorved platformen i Afrika styrkes. Offentliggørelsen følger i hælene på implementeringen af Andersen-brandet af det stiftende amerikanske medlemsfirma i 2019 og medlemsfirmaer i Europa, Latinamerika og Mellemøsten i 2020.
Andersen Global-medlemsfirmaer i Nigeria og Kenya, som tidligere opererede under brandet ”Andersen Tax”, vil nu overgå til det kendte brand ”Andersen”. Tidligere samarbejdspartnere i Sydafrika (Tabacks), Tunesien (Jelil Bouraoui & Associates) samt Mauritius og Seychellerne (ATax Advisors) vil ligeledes implementere det nye Andersen-brand. Andersen Global byder også medlemsfirmaer på Elfenbenskysten (Mondon Conseil) og i Mozambique (Isálcio Mahanjane Advogado & Associados) velkommen.
At arbejde under et kendt brand demonstrerer regionens evne til at tilbyde ukomplicerede tjenester globalt sammen med de andre Andersen Global-medlemsfirmaer. Andersen Global er via sine medlemsfirmaer og samarbejdspartnere repræsenteret i 45 lande på kontinentet, indbefattet juridiske tjenester i 41 lande.
”I de sidste mange år har vores platform i Afrika haft en høj prioritet i overensstemmelse med vores forpligtelse over for kundeservice og tilvejebringelsen af ukomplicerede skatte- og juridiske tjenester globalt. Efterhånden som økonomien og markederne fortsætter med at ændre sig og blive mere globale, er vores organisations behov for omfattende løsninger på tværs af landegrænser blevet vigtigere. Igennem vores udvidelsesbestræbelser og foreningen af vores afrikanske medlemsfirmaer under et kendt brand, har vi opnået vores mål om at have det største juridiske fodaftryk på kontinentet” udtalte Mark Vorsatz, Andersen Global bestyrelsesformand og adm. direktør hos Andersen. ”Vi forbliver forpligtet over for at være et af de mest betydningsfulde skatte- og advokatfirmaer når det gælder medarbejderstab, geografisk dækning og – vigtigst af alt – kvalitet”.
For yderligere at styrke sin ledelsesstruktur i regionen, har organisationens afrikanske bestyrelse valgt Jelil Bouraoui som virksomhedsleder hos Andersen i Tunesien til at repræsentere regionen i bestyrelsen hos Andersen Global. Derudover vil Olaleye Adebiyi, virksomhedsleder hos Andersen i Nigeria, og Derrick Kaufmann, virksomhedsleder hos Andersen i Sydafrika, tjene som assisterende virksomhedsledere i regionen. Jelil, Olaleye og Derrick vil arbejde tæt sammen for at administrere organisationen i Afrika og støtte regionens fremtidige udvidelsesbestræbelser.
Grundlaget for Andersens globale platform går helt tilbage til 2002, hvor 23 tidligere Arthur Andersen-partnere oprettede et firma, der kun beskæftigede sig med skat, WTAS LLC, som efterfulgtes af Andersen Global (tidligere WTAS Global) i 2013. Det efterfølgende år tog det amerikanske medlemsfirma brandet ”Andersen Tax” til sig, efterfulgt af medlemsfirmaer i Latinamerika, Europa og Afrika. Andersen Tax debuterede i Nigeria i 2017 og i Kenya i 2018, og regionen er siden blevet udvidet til i dag at omfatte mere end 65 lokationer, 1.000 medarbejdere inden for skat og jura og næsten 200 partnere.
I løbet af det næste år fortsætter medlemsfirmaer i Canada og Israel med at implementere det fælles Andersen-brand, mens Andersen Global fortsætter med at udvide på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 254 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210224005456/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum